RecruitingPhase 1NCT05445804

Oral Cannabidiol for Tobacco Cessation

Sponsor

Johns Hopkins University

Enrollment

50 participants

Start Date

Nov 1, 2022

Study Type

INTERVENTIONAL

Conditions

Tobacco Use Disorder Tobacco Dependence Tobacco Use Cessation Tobacco Smoking Tobacco Use

Summary

Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 300 mg Cannabidiol, a drug called 600 mg Cannabidiol, and others for people with tobacco dependence, tobacco smoking, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.